By Kevin Amado ·
45 of 57 tests passed, with Nvidia and the Japanese banks in front
From November 12 to November 20, 57 tests at 55 picks were decided, and 45 passed. Nvidia, Cisco and the three big Japanese banks reported strong results, while four Chinese companies and Intuit missed their tests. On November 21, the list has 888 active companies, and 47 picks report from November 23 to December 3.
45 of 57 decided tests passed
From November 12 to November 20, 57 tests at 55 picks were decided, and 45 passed. November 12 had 10 passes and 2 failures. November 19 was the busiest day, with 10 passes and 5 failures.
The 12 failures had different causes. Intuit cut its fiscal 2027 revenue growth guidance to 8% to 9%, and its Credit Karma growth guidance to 3% to 7%, from 11% to 13%. Gap lowered its fiscal 2026 outlook to roughly flat net sales. Nebius now expects 2026 revenue at the low end of its range, and its $7 billion run rate moved to February 2027 from December 2026. Viking's adjusted EBITDA fell 4.3% to $673.5 million, because low river water cut revenue by about $100 million, although its 2027 advance bookings are 17% ahead.
Two failures were not about a quarter. Kraft Heinz gave milestones through 2029 at its Investor Day, but no numeric volume or margin targets, and it expects adjusted operating income to fall by a low single-digit percent in 2027. Summit received a complete response letter from the FDA on November 15, because its HARMONi study did not show a statistically significant overall survival benefit.
Sucro's Q3 income from operations, without unrealized gains and before depreciation, was about US$5.1 million, below the test of US$8 million.
AI suppliers grew, and so did their commitments
Nvidia reported record revenue of $115.8 billion for the quarter that ended October 25, up 103% from last year and up 20% from the second quarter. Data center revenue was $107.6 billion, and the gross margin of 74.8% was above the guide of about 74%. It guided the next quarter to $130.0 billion, plus or minus 3%, with an extra week and no data center compute revenue from China.
The cost side grew too. Nvidia's supply commitments rose to $390 billion from $279 billion in the second quarter, mainly for memory. Accounts receivable were $81.0 billion, or 64 days of sales, up from 60 days.
Other suppliers showed the same demand. Cisco's revenue grew 24% to a record $18.5 billion, but its non-GAAP gross margin fell to 65.6% from 68.1%. Applied Materials had record revenue of $10.41 billion, up 53%, and Keysight's orders rose 53% to $2,339 million.
The three big Japanese banks raised targets and bought back stock
All three Japanese megabanks reported first-half results on November 13 and raised their full-year targets. MUFG raised its target to ¥2,800.0 billion after a first-half profit of ¥1,630,897 million, and approved a buyback of up to ¥200 billion. SMFG raised its forecast to ¥1,900 billion and approved a buyback of up to ¥220 billion. Mizuho's first-half profit rose 29.9% to ¥896.5 billion, and it raised its fiscal 2026 target to ¥1,600.0 billion, raised its dividend estimate to ¥200 and announced a buyback of up to ¥200.0 billion.
The quality of the numbers differs. SMFG's total credit cost rose to ¥133,527 million from ¥90,168 million, and it also corrected its financial statements for the year ended March 31, 2026.
Retailers grew sales, and the market judged them very differently
Almost every US retailer grew comparable sales, but the share price reactions were far apart. Ross grew comparable store sales 8% and raised its fiscal 2026 EPS guidance to $8.75 to $8.84. TJX grew comparable sales 4%, raised its fiscal 2027 EPS guidance, and its shares closed at $140.30 on November 18, up 8.0% from $129.85. Lowe's grew comparable sales 1.8% and raised its 2026 outlook, and Home Depot grew 2.2%, with comparable transactions down only 0.5%.
Williams-Sonoma grew comparable brand revenue 5.1% and kept its guidance, yet its shares closed at $220.66 on November 19, down from $260.09 the day before. Part of its quarter came from $29.3 million of IEEPA tariff refunds booked as a cut in cost of goods sold. Gap went the other way: Gap brand comparable sales rose 9%, but Old Navy was flat and Athleta fell 15%, and the company lowered its outlook.
Four Chinese companies missed, five passed
Baidu, H World, NetEase and PDD all failed their tests, each for its own reason. Baidu's online marketing revenue fell 22%, faster than the 19% fall in the second quarter, although AI Cloud Infrastructure revenue grew 94%. H World's same-hotel RevPAR in China fell 4.4%, after a fall of 3.0% in the second quarter. NetEase's games revenue fell 1.7% to RMB22.9 billion. PDD's operating profit rose 25% to RMB 31.2 billion, but revenue stayed flat at RMB 108.3 billion.
Five Chinese picks passed: Alibaba's external Cloud revenue grew 64%, JD.com's New Businesses loss fell to RMB9.6 billion from RMB15.7 billion, Tencent Music's membership revenue grew 9.2%, KE Holdings kept a gross margin of 27.7%, and ZTO's core express unit price rose 13.7%. JD.com also completed its takeover offer for CECONOMY, the owner of MediaMarkt and Saturn, buying 59.8% for EUR 1,335 million at EUR 4.60 per share.
Deals, offers and sales
Intuit agreed to sell Mailchimp to Bending Spoons for about $3.68 billion: $3.31 billion in cash and $368 million in Bending Spoons stock. Bending Spoons also agreed to sell 32.5 million new shares at $40 per share to institutional investors, for expected gross proceeds of $1.30 billion. Palo Alto Networks agreed to buy Applied Compute for $4.5 billion in its own shares.
Santander raised the exchange ratio of its planned offer for the part of Banco Santander Brasil that it does not own by 5%, to 0.4260 new Santander shares for each unit or ADS. Quebecor improved its non-binding proposal for TELUS on November 9 to C$6.35 in cash and 0.1700 Quebecor Class B share for each TELUS share. Sempra closed the sale of 45% of Sempra Infrastructure Partners and received $4.56 billion in cash.
One FDA rejection, two approvals and a dropped study
Besides the Summit rejection, the FDA approved two AstraZeneca medicines on November 16: Klygefa for generalised myasthenia gravis, and Imfinzi with enfortumab vedotin for muscle-invasive bladder cancer. Incyte decided not to start MAESTRA-3, a planned Phase 3 study of its CDK2 inhibitor in ovarian cancer.
Four FDA decisions are next: GSK's neladalkib and Bridgebio's BBP-418 on November 27, and Roche's giredestrant and Vertex's povetacicept on November 30.
47 picks report from November 23 to December 3
From November 23 to December 3, 47 picks report, and 26 of those dates are still estimates. November 24 has 11 reports, among them Autodesk, Medtronic, Dell, Analog Devices and Couche-Tard. December 3 is the busiest day, with 13: Royal Bank of Canada, Toronto-Dominion and CIBC, Lululemon, Kroger, Dollar General and Ulta among them.
In between, Deere and Zoom report on November 25, Marvell and CrowdStrike on December 1, and Salesforce and Snowflake on December 2.